Gunnar Birgegård

The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

Wondergem, Marielle J.; Almeida, Antonio; Brolin, Janaki; Fernandez de Larrea, Carlos et al.

Ingår i HemaSphere, 2022

• DOI för The Progress Test of the European Hematology Association: A New Tool for Continuous Learning
• Ladda ner fulltext (pdf) av The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Alvarez-Larran, Alberto; Sant'Antonio, Emanuela; Harrison, Claire; Kiladjian, Jean-Jacques et al.

Ingår i The Lancet Haematology, 2021

• DOI för Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Navarro, Jose-Tomas; Birgegård, Gunnar; Strivens, Janet; Hollegien, Wietske W. G. et al.

Ingår i HemaSphere, 2019

• DOI för The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe
• Ladda ner fulltext (pdf) av The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Birgegård, Gunnar; Samuelsson, Jan; Ahlstrand, Erik; Ejerblad, Elisabeth et al.

Ingår i European Journal of Haematology, s. 235-240, 2019

• DOI för Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study

Birgegård, Gunnar; Folkvaljon, Folke; Garmo, Hans; Holmberg, Lars et al.

Ingår i Leukemia Research, s. 105-109, 2018

• DOI för Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study

The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

Wondergem, Marielle J.; Almeida, Antonio; Brolin, Janaki; Fernandez de Larrea, Carlos et al.

Ingår i HemaSphere, 2022

• DOI för The Progress Test of the European Hematology Association: A New Tool for Continuous Learning
• Ladda ner fulltext (pdf) av The Progress Test of the European Hematology Association: A New Tool for Continuous Learning

The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Navarro, Jose-Tomas; Birgegård, Gunnar; Strivens, Janet; Hollegien, Wietske W. G. et al.

Ingår i HemaSphere, 2019

• DOI för The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe
• Ladda ner fulltext (pdf) av The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Birgegård, Gunnar; Samuelsson, Jan; Ahlstrand, Erik; Ejerblad, Elisabeth et al.

Ingår i European Journal of Haematology, s. 235-240, 2019

• DOI för Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study

Birgegård, Gunnar; Folkvaljon, Folke; Garmo, Hans; Holmberg, Lars et al.

Ingår i Leukemia Research, s. 105-109, 2018

• DOI för Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

Birgegård, Gunnar; Besses, Carlos; Griesshammer, Martin; Gugliotta, Luigi et al.

Ingår i Haematologica, s. 51-60, 2018

• DOI för Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
• Ladda ner fulltext (pdf) av Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

Scotch, Allison H; Kosiorek, Heidi; Scherber, Robyn; Dueck, Amylou C et al.

Ingår i Leukemia Research, s. 34-40, 2017

• DOI för Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Geyer, Holly L.; Kosiorek, Heidi; Dueck, Amylou C.; Scherber, Robyn et al.

Ingår i Haematologica, s. 85-93, 2017

• DOI för Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
• Ladda ner fulltext (pdf) av Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY

Birgegård, Gunnar; Folkvaljon, Yasin; Garmo, Hans; Holmberg, Lars et al.

Ingår i Haematologica, s. 282-282, 2017

Which patients with myelofibrosis should receive ruxolitinib therapy?: ELN-SIE evidence-based recommendations

Marchetti, M.; Barosi, G.; Cervantes, F.; Birgegård, Gunnar et al.

Ingår i Leukemia, s. 882-888, 2017

• DOI för Which patients with myelofibrosis should receive ruxolitinib therapy?: ELN-SIE evidence-based recommendations

Treatment of high risk ET: data from the EXELS study

Birgegård, Gunnar; Besses, C.; Griesshammer, M.; Gugliotta, L. et al.

Ingår i Leukemia Research, 2016

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial

Birgegård, Gunnar; Henry, David; Glaspy, John; Chopra, Rakesh et al.

Ingår i Pharmacotherapy, s. 402-414, 2016

• DOI för A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial
• Ladda ner fulltext (pdf) av A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease

Geyer, Holly; Scherber, Robyn; Kosiorek, Heidi; Dueck, Amylou C et al.

Ingår i Journal of Clinical Oncology, s. 151-+, 2016

• DOI för Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease

Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia: Results From The Prospective Long-Term Observational Exels Study

Gugliotta, L.; Tortorella, G.; Besses, C.; Griesshammer, M. et al.

Ingår i Haematologica, s. 557-557, 2016

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

Geyer, Holly L.; Andreasson, Bjorn; Kosiorek, Heidi E.; Dueck, Amylou C. et al.

Ingår i Cancer, s. 1888-1896, 2016

• DOI för The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

Development Of An Mf Patient Reported Outcome (Pro) Tool For Fda Qualification: Comprehensive Literature Search And Physician Cognitive Debriefing Results

Geyer, H.; Kosiorek, H.; Dueck, A.; Slot, S. et al.

Ingår i Haematologica, s. 564-564, 2016

SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT

Scherber, R.; Dueck, A.; Geyer, H.; Kosiorek, H. et al.

Ingår i Haematologica, s. 557-558, 2016

Rate Of Malignant Transformation In High Risk Et During 5 Years Of Follow-Up Of Cytoreductive Therapy

Birgegård, Gunnar; Folkvaljon, Y.; Garmo, H.; Besses, C. et al.

Ingår i Haematologica, s. 96-96, 2016

Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features: An Analysis By The Mpn Quality Of Life International Study Group

Geyer, H.; Scherber, R.; Kosiorek, H.; Dueck, A. et al.

Ingår i Haematologica, s. 555-555, 2016

Advances and challenges in the management of essential thrombocythemia

Birgegård, Gunnar

Ingår i Therapeutic advances in hematology, s. 142-156, 2015

• DOI för Advances and challenges in the management of essential thrombocythemia

Treatment of essential thrombocythaemia in Europe: an observational study of 3649 high-risk patients in EXELS

Griesshammer, M.; Stegelmann, F.; Mohr, A.; Matzdorff, A. et al.

Ingår i Oncology Research and Treatment, s. 216-216, 2015

Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation: A pilot study

Svanberg, Anncarin; Öhrn, Kerstin; Birgegård, Gunnar

Ingår i European Journal of Oncology Nursing, s. 50-53, 2015

• DOI för Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation: A pilot study

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

Barosi, G; Tefferi, A; Besses, C; Birgegård, Gunnar et al.

Ingår i Leukemia, s. 20-26, 2015

• DOI för Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

Dignass, Axel U; Gasche, Christoph; Bettenworth, Dominik; Birgegård, Gunnar et al.

Ingår i Journal of Crohn's & Colitis, s. 211-222, 2015

• DOI för European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting

Svanberg, Anncarin; Birgegård, Gunnar

Ingår i Oncology, s. 31-36, 2015

• DOI för Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting

Treatment of essential thrombocythaemia in Europe: an observational study of 3649 high-risk patients in EXELS

Harrison, C.; Tiplady, C.; Fernandes, S.; Knechtli, C. et al.

Ingår i British Journal of Haematology, s. 7-7, 2015

RISK FACTORS FOR THROMBOHEMORRHAGIC AND TRANSFORMATION EVENTS IN 3649 HIGH-RISK PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: RESULTS FROM THE PROSPECTIVE LONG-TERM OBSERVATIONAL EXELS STUDY

Birgegård, Gunnar; Besses, C.; Griesshammer, M.; Gugliotta, L. et al.

Ingår i Haematologica, s. 160-161, 2015

PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)

Geyer, H.; Kosiorek, H.; Scherber, R.; Dueck, A. et al.

Ingår i Haematologica, s. 261-262, 2015

Development of a Progress Test Based on the EHA Curriculum and EHA CV Passport, Used for Yearly Evaluation of Hematology Residency In Sweden

Ungerstedt, J.; Eriksson, Anna; Olander, E.; Bergfelt, Emma et al.

Ingår i Haematologica, s. 776-776, 2015

Treatment Of Essential Thrombocythaemia In Europe: An Observational Study Of 3649 High-Risk Patients In Exels

Gugliotta, L.; Specchia, G.; Gaidano, G.; Scalzulli, P. R. et al.

Ingår i Haematologica, s. 43-43, 2015

Treatment Of Essential Thrombocythemia In Europe: Observational Study Of 3649 Patients Of High Risk (Exels)

Besses, C.; Bello-Lopez, J. L.; De la Serna, J.; Hernandez-Boluda, J. C. et al.

Ingår i Haematologica, s. 29-29, 2015

Gender Differences and MPN Symptom Burden: An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG)

Geyer, H.; Emanuel, R.; Dueck, A.; Kiladjian, J. J. et al.

Ingår i Haematologica, s. 396-397, 2014

Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy

Hedenus, Michael; Karlsson, Torbjörn; Ludwig, Heinz; Rzychon, Beate et al.

Ingår i Medical Oncology, s. 302, 2014

• DOI för Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy
• Ladda ner fulltext (pdf) av Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Geyer, Holly L.; Scherber, Robyn M.; Dueck, Amylou C.; Kiladjian, Jean-Jacques et al.

Ingår i Blood, s. 3803-3810, 2014

• DOI för Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Does anything work for anaemia in myelofibrosis?

Birgegard, Gunnar

Ingår i Baillière's Best Practice & Research, s. 175-185, 2014

• DOI för Does anything work for anaemia in myelofibrosis?

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid (R) efficacy and long-term safety study

Gugliotta, Luigi; Besses, Carlos; Griesshammer, Martin; Harrison, Claire et al.

Ingår i Haematologica, s. 679-687, 2014

• DOI för Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid (R) efficacy and long-term safety study

Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients

Geyer, Holly Lynn; Scherber, Robyn M.; Dueck, Amylou Constance; Kiladjian, Jean-Jacques et al.

Ingår i Blood, 2014

Treatment of Essential Thrombocythemia in Europe: An Observational Study of 3649 High-Risk Patients in Exels

Birgegård, Gunnar; Besses, Carlos; Griesshammer, Martin; Gugliotta, Luigi et al.

Ingår i Blood, 2014

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

Besses, Carlos; Kiladjian, Jean-Jacques; Griesshammer, Martin; Gugliotta, Luigi et al.

Ingår i Leukemia Research, s. 162-168, 2013

• DOI för Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Ejerblad, Elisabeth; Kvasnicka, Hans M; Thiele, Jürgen; Andreasson, Björn et al.

Ingår i Hematology, s. 8-13, 2013

• DOI för Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged > 80 Years: An Interim Analysis of the EXELS Study

Kiladjian, Jean-Jacques; Besses, Carlos; Griesshammer, Martin; Gugliotta, Luigi et al.

Ingår i Clinical drug investigation, s. 55-63, 2013

• DOI för Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged > 80 Years: An Interim Analysis of the EXELS Study

Cytoreductive treatment patterns for essential thrombocythaemia in Europe: analysis of 3643 patients in the EXELS study

Harrison, C.; Besses, C.; Kiladjian, J. J.; Griesshammer, M. et al.

Ingår i British Journal of Haematology, s. 17-17, 2013

The exels study: Real-world cytoreductive treatment patterns for essential thrombocythaemia in Europe (analysis of 3643 patients)

Griesshammer, M.; Gugliotta, L.; Harrison, C.; Besses, C. R. et al.

Ingår i Onkologie (Basel), s. 111-111, 2013

Addition of aprepitant (Emend (R)) to standard antiemetic care for seven days post-chemotherapy before stem cell transplantation gives significant reduction of vomiting

Svanberg, Anncarin; Birgegård, Gunnar

Ingår i Bone Marrow Transplantation, 2013

Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis

Lönnberg, Maria; Garle, Mats; Lönnberg, Lina; Birgegård, Gunnar

Ingår i Journal of Pharmaceutical and Biomedical Analysis, s. 187-192, 2013

• DOI för Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis
• Ladda ner fulltext (pdf) av Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis

Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms

Johansson, Peter; Mesa, Ruben; Scherber, Robyn; Abelsson, Johanna et al.

Ingår i Leukemia and Lymphoma, s. 441-444, 2012

• DOI för Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Abelsson, J; Merup, M; Birgegård, Gunnar; WeisBjerrum, O et al.

Ingår i Bone Marrow Transplantation, s. 380-386, 2012

• DOI för The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Rapid detection of erythropoiesis-stimulating agents in urine and serum

Lönnberg, Maria; Andrén, Maria; Birgegård, Gunnar; Drevin, Malin et al.

Ingår i Analytical Biochemistry, s. 101-114, 2012

• DOI för Rapid detection of erythropoiesis-stimulating agents in urine and serum

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Emanuel, Robyn M; Dueck, Amylou C; Geyer, Holly L; Kiladjian, Jean-Jacques et al.

Ingår i Journal of Clinical Oncology, s. 4098-4103, 2012

• DOI för Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Five year follow-up of survival and relapse in patients who received cryotherapy during high dose chemotherapy for stem cell transplantation shows no safety concerns

Svanberg, Anncarin; Öhrn, Kerstin; Birgegård, Gunnar

Ingår i European Journal of Cancer Care, s. 822-828, 2012

• DOI för Five year follow-up of survival and relapse in patients who received cryotherapy during high dose chemotherapy for stem cell transplantation shows no safety concerns

The effect of cryotherapy on oral mucosa: a study in healthy volunteers

Svanberg, Anncarin; Öhrn, Kerstin; Broström, Hans; Birgegård, Gunnar

Ingår i Medical Oncology, s. 3587-3591, 2012

• DOI för The effect of cryotherapy on oral mucosa: a study in healthy volunteers

The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients

Geyer, Holly Lynn; Dueck, Amylou C.; Emanuel, Robyn M.; Kiladjian, Jean-Jacques et al.

Ingår i Blood, s. 1731, 2012

Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients

Emanuel, Robyn M.; Dueck, Amylou C.; Geyer, Holly Lynn; Kiladjian, Jean-Jacques et al.

Ingår i Blood, s. 1726, 2012

Combination of Cytoreductive Therapies in Patients with Essential Thrombocythemia: A Preliminary Report From the EXELS Study

Gugliotta, Luigi; Besses, Carlos; Griesshammer, Martin; Harrison, Claire N. et al.

Ingår i Blood, s. 2842, 2012

Webbaserad pedagogisk meritportfölj: från idé till verklighet

Johansson, Jakob; Apelgren, Karin; Birgegård, Gunnar; Grydén, Martin et al.

Ingår i Högre Utbildning, s. 27-37, 2011

Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?

Aapro, Matti; Beguin, Yves; Birgegård, Gunnar; Gascon, Pere et al.

Ingår i Journal of Clinical Oncology, 2011

• DOI för Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Scherber, Robyn; Dueck, Amylou C.; Johansson, Peter; Barbui, Tiziano et al.

Ingår i Blood, s. 401-408, 2011

• DOI för The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions

Nilsson-Ehle, Herman; Birgegård, Gunnar; Samuelsson, Jan; Antunovic, Petar et al.

Ingår i European Journal of Haematology, s. 244-252, 2011

• DOI för Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Barbui, Tiziano; Barosi, Giovanni; Birgegård, Gunnar; Cervantes, Francisco et al.

Ingår i Journal of Clinical Oncology, s. 761-770, 2011

• DOI för Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

Björkholm, Magnus; Derolf, Asa R; Hultcrantz, Malin; Kristinsson, Sigurdur Y et al.

Ingår i Journal of Clinical Oncology, s. 2410-2415, 2011

• DOI för Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron

Birgegård, Gunnar; Schneider, Karin; Ulfberg, J.

Ingår i Vox Sanguinis, s. 354-361, 2010

• DOI för High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

Barosi, Giovanni; Birgegård, Gunnar; Finazzi, Guido; Griesshammer, Martin et al.

Ingår i British Journal of Haematology, s. 961-963, 2010

• DOI för A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

Oral cryotherapy reduces mucositis and improves nutrition: a randomised controlled trial

Svanberg, Anncarin; Öhrn, Kerstin; Birgegård, Gunnar

Ingår i Journal of Clinical Nursing, s. 2146-2151, 2010

• DOI för Oral cryotherapy reduces mucositis and improves nutrition: a randomised controlled trial

High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio

Tobiasson, Magnus; Alyass, Bassam; Söderlund, Susanne; Birgegård, Gunnar

Ingår i Medical Oncology, s. 105-107, 2010

• DOI för High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio

Reassessments of ESAs for cancer treatment in the US and Europe

Bennett, Charles L.; McKoy, June M.; Henke, Michael; Silver, Samuel M. et al.

Ingår i Oncology, s. 260-268, 2010

New perspectives in managing myeloproliferative disorders: focus on the patient

Birgegård, Gunnar

Ingår i Hematological Oncology, s. 5-7, 2009

• DOI för New perspectives in managing myeloproliferative disorders: focus on the patient

Medical interns' view of their undergraduate medical education in Uppsala: an alumnus study with clear attitude differences between women and men

Hoppe, Astrid; Persson, Elisabeth; Birgegård, Gunnar

Ingår i Medical teacher, s. 426-432, 2009

• DOI för Medical interns' view of their undergraduate medical education in Uppsala: an alumnus study with clear attitude differences between women and men

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

Barosi, Giovanni; Birgegård, Gunnar; Finazzi, Guido; Griesshammer, Martin et al.

Ingår i Blood, s. 4829-4833, 2009

• DOI för Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

Bone marrow fibrosis and diagnosis of essential thrombocythemia

Thiele, Juergen; Kvasnicka, Hans Michael; Vardiman, James W.; Orazi, Attilio et al.

Ingår i Journal of Clinical Oncology, 2009

• DOI för Bone marrow fibrosis and diagnosis of essential thrombocythemia

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Palmblad, Jan; Björkholm, Magnus; Kutti, Jack; Lärfars, Gerd et al.

Ingår i International Journal of Medical Sciences, s. 87-91, 2008

Randomized comparison of student-activating and traditional lecture: no learning difference

Birgegård, Gunnar; Persson, Elisabeth; Hoppe, Astrid

Ingår i Medical teacher, s. 819-819, 2008

• DOI för Randomized comparison of student-activating and traditional lecture: no learning difference

MED NORD - A tool for measuring medical students' well-being and study orientations

Lonka, Kirsti; Sharafi, Parvaneh; Karlgren, Klas; Masiello, Italo et al.

Ingår i Medical teacher, s. 72-79, 2008

• DOI för MED NORD - A tool for measuring medical students' well-being and study orientations

Managing anemia in lymphoma and multiple myeloma

Birgegård, Gunnar

Ingår i Therapeutics and clinical risk management, s. 527-539, 2008

• DOI för Managing anemia in lymphoma and multiple myeloma

Den nya läkarutbildningen i Uppsala: Fallbaserad, integrerad och med tidig patientkontakt

Birgegård, Gunnar; Sandler, Stellan; Bergsten, Johannes; Nilsson, Olle

Ingår i Läkartidningen, s. 3724-8, 2008

Enkätstudie om AT-läkares syn på sin grundutbildning: Tydliga attitydskillnader mellan kvinnor och män

Hoppe, Astrid; Persson, Elisabeth M.; Birgegård, Gunnar

Ingår i Läkartidningen, s. 620-3, 2008

Erythropoietins should be used according to guidelines

Aapro, Matti S.; Birgegård, Gunnar; Bokemeyer, Carsten; Cornes, Paul et al.

Ingår i The Lancet Oncology, s. 412-3, 2008

• DOI för Erythropoietins should be used according to guidelines

Epoetin treatment in haernatologic malignancy: How to improve response?

Birgegård, Gunnar

Ingår i European Journal of Cancer Supplements, s. 436-437, 2007

• DOI för Epoetin treatment in haernatologic malignancy: How to improve response?

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Hedenus, M.; Birgegård, Gunnar; Näsman, P.; Ahlberg, L. et al.

Ingår i Leukemia, s. 627-632, 2007

• DOI för Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

Barosi, G.; Besses, C.; Birgegård, Gunnar; Briere, J. et al.

Ingår i Leukemia, s. 277-280, 2007

• DOI för A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment

Birgegård, Gunnar; Dahl, Fredrik; Glimelius, Bengt; Landegren, Ulf

Ingår i Medical Oncology, s. 318-322, 2007

• DOI för Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Ahlqvist-Rastad, Jane; Albertsson, Maria; Bergh, Jonas; Birgegård, Gunnar et al.

Ingår i Medical Oncology, s. 267-272, 2007

• DOI för Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Patient attitudes, behaviours, and other factors considered by doctors when estimating cancer patients' anxiety and desire for information

Fröjd, Camilla; Lampic, Claudia; Larsson, Gunnel; Birgegård, Gunnar et al.

Ingår i Scandinavian Journal of Caring Sciences, s. 523-529, 2007

• DOI för Patient attitudes, behaviours, and other factors considered by doctors when estimating cancer patients' anxiety and desire for information

Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy-a randomized controlled trial

Svanberg, Anncarin; Birgegård, Gunnar; Öhrn, Kerstin

Ingår i Supportive Care in Cancer, s. 1155-1161, 2007

• DOI för Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy-a randomized controlled trial

Essential thrombocythaemia treatment options: addressing patient-specific needs

Birgegård, Gunnar

Ingår i European Journal of Haematology, s. 27-31, 2007

• DOI för Essential thrombocythaemia treatment options: addressing patient-specific needs

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Tefferi, Ayalew; Thiele, Juergen; Orazi, Attilio; Kvasnicka, Hans Michael et al.

Ingår i Blood, s. 1092-1097, 2007

• DOI för Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment

Hultdin, Magnus; Sundström, Gunnel; Wahlin, Anders; Lundström, Berith et al.

Ingår i Medical Oncology, s. 63-70, 2007

• DOI för Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment

Uppsalaprofilen i läkarutbildningen. Människokunskap och biologi förenas.

Birgegard, Gunnar; Eriksson, Ulf

Ingår i Läkartidningen, s. 299-302, 1995

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Alvarez-Larran, Alberto; Sant'Antonio, Emanuela; Harrison, Claire; Kiladjian, Jean-Jacques et al.

Ingår i The Lancet Haematology, 2021

• DOI för Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Barbuil, Tiziano; Tefferi, Ayalew; Vannucchi, Alessandro M.; Passamonti, Francesco et al.

Ingår i Leukemia, s. 1057-1069, 2018

• DOI för Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

Birgegård, Gunnar

Ingår i Current Hematologic Malignancy Reports, s. 348-355, 2016

• DOI för The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
• Ladda ner fulltext (pdf) av The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

Pharmacological management of essential thrombocythemia

Birgegård, Gunnar

Ingår i Expert Opinion on Pharmacotherapy, s. 1295-1306, 2013

• DOI för Pharmacological management of essential thrombocythemia

Long-term management of thrombocytosis in essential thrombocythaemia

Birgegård, Gunnar

Ingår i Annals of Hematology, s. 1-10, 2009

• DOI för Long-term management of thrombocytosis in essential thrombocythaemia

The role of iron supplementation during epoietin treatment for cancer-related anemia

Hedenus, Michael; Birgegård, Gunnar

Ingår i Medical Oncology, s. 105-115, 2009

• DOI för The role of iron supplementation during epoietin treatment for cancer-related anemia

15. Anemi och järn

Birgegård, Gunnar

Ingår i Blodets sjukdomar, s. 195-213, Studentlitteratur, 2012

Övriga myeloproliferativa Sjukdomar

Birgegård, Gunnar

Ingår i Internmedicin, s. 410-418, Liber, 2011

Järnbristanemi och sekundär anemi

Birgegård, Gunnar

Ingår i Internmedicin, s. 365-371, Liber, 2011